EpiEndo Commences LPS Challenge Trial for Lead Candidate EP395
Regulatory approval for proof of pharmacology study for the first non-antibiotic macrolideREYKJAVIK, Iceland, August 31, 2022 / B3C newswire / -- EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has received...